Victory Capital Management Inc. acquired a new stake in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 45,040 shares of the biopharmaceutical company’s stock, valued at approximately $164,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. RA Capital Management LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at about $18,727,000. Vanguard Group Inc. raised its holdings in AVEO Pharmaceuticals by 48.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the period. EAM Investors LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter valued at about $1,979,000. Cannell Peter B & Co. Inc. raised its holdings in AVEO Pharmaceuticals by 22.9% in the 2nd quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 20,500 shares during the period. Finally, Rehmann Capital Advisory Group acquired a new position in AVEO Pharmaceuticals in the 3rd quarter valued at about $193,000. Hedge funds and other institutional investors own 50.94% of the company’s stock.

Several equities analysts have weighed in on AVEO shares. Piper Jaffray Companies lifted their target price on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the company an “overweight” rating in a research report on Monday, August 28th. BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. started coverage on AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price for the company. B. Riley started coverage on AVEO Pharmaceuticals in a research report on Monday, November 13th. They issued a “buy” rating and a $5.00 target price for the company. Finally, Seaport Global Securities reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $4.05.

AVEO Pharmaceuticals, Inc. (AVEO) opened at $3.00 on Wednesday. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals, Inc. has a 52-week low of $0.50 and a 52-week high of $4.24.

COPYRIGHT VIOLATION NOTICE: “Victory Capital Management Inc. Takes $164,000 Position in AVEO Pharmaceuticals, Inc. (AVEO)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/victory-capital-management-inc-takes-164000-position-in-aveo-pharmaceuticals-inc-aveo/1732023.html.

AVEO Pharmaceuticals Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.